Bio-Techne (TECH) Stock Forecast & Price Target
Score
Bio-Techne Corporation price target
| TECH | |
|---|---|
| Low | $50.00 |
| Average | $65.78 |
| High | $73.00 |
| Upside vs current price | -9.6% |
The average target of $65.78 is -9.6% versus the current TECH price of $72.78.
Bio-Techne Corporation analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 0 |
| Hold | 12 |
| Sell | 1 |
| Strong sell | 0 |
| Consensus | Hold |
13 analysts cover TECH.
Bio-Techne Corporation EPS and revenue estimates
The estimate table for the Bio-Techne Corporation keeps 2027 EPS $2.05, 2028 EPS $2.36, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2027 | $2.05 | $1.27B |
| 2028 | $2.36 | $1.40B |
Is Bio-Techne Corporation a buy or sell?
Of the 13 analysts covering Bio-Techne Corporation, 0 rate it a buy (0 strong buy and 0 buy), 12 rate it a hold, and 1 rates it a sell (1 sell and 0 strong sell).
The TECH consensus label is Hold, beside 0 buy-side ratings and 1 sell-side ratings.
The average target of $65.78 implies -9.6% versus the current price of $72.78.
the Bio-Techne Corporation closes with 0 buy-side ratings and 1 on the sell side. The headcount is Hold.
Reading the Bio-Techne Corporation forecast
Between the TECH low of $50.00 and the high of $73.00, the average target is $65.78.
From today's $72.78 print, the TECH average target is -9.6% away.
Most of the TECH coverage agrees: 0 of 13 analysts are on the buy side, 12 are at hold, and 1 is on the sell side, and the published consensus is Hold.
TECH has both upgrades (0) and downgrades (1) in the recent window.
Earnings estimates for TECH are rising: 2027 $2.05, then 2028 $2.36.
TECH coverage is thin at 13 analysts, and one revision moves the average.
Bio-Techne Corporation forecast questions
What is the TECH price target?
The published range for TECH is $50.00 to $73.00, with an average of $65.78. That average is -9.6% versus the current price of $72.78.
Is Bio-Techne Corporation a buy or sell?
Of the 13 analysts covering Bio-Techne Corporation, 0 rate it a buy, 12 rate it a hold, and 1 rates it a sell. The consensus is Hold, which for TECH is 0 on the buy side, 12 at hold, and 1 on the sell side.
What is the EPS estimate for Bio-Techne Corporation?
Analyst EPS estimates for Bio-Techne Corporation: 2027 $2.05, 2028 $2.36.
What is the revenue estimate for Bio-Techne Corporation?
Analyst revenue estimates for Bio-Techne Corporation: 2027 $1.27B, 2028 $1.40B.
How many analysts cover TECH?
13 analysts cover TECH. Their consensus on TECH is Hold, across those 13.